Deal Positive for Sarepta (SRPT), Summit (SMMT) and DMD Community - Oppenheimer

Oppenheimer analyst Michelle Gilson reiterated an Outperform rating and $76 price target on Sarepta Therapeutic (NASDAQ: SRPT) after the company Sarepta and Summit (NASDAQ: SMMT) announced a licensing and collaboration agreement for EU rights to Summit's utrophin modulation programs for the treatment of Duchenne muscular dystrophy. Sarepta will pay Summit $40M upfront as part of the agreement, and will receive rights to Summit's utrophin modulators (including ezutromid and other follow-on utrophin modulators) in the EU, Turkey and the Commonwealth of Independent States. Additionally, Sarepta has received an option for Latin American rights to utrophin modulators.

"We view this agreement as positive for Sarepta and Summit, as well as the DMD community, as we believe significant synergies in research and development can be realized, mitigating some difficulties of clinical development in DMD," Gilson. "Sarepta has pro forma cash of $395M, following this agreement and 3Q16 offering."

For an analyst ratings summary and ratings history on Sarepta Therapeutic click here. For more ratings news on Sarepta Therapeutic click here.

Shares of Sarepta Therapeutic closed at $60.95 yesterday.

You May Also Be Interested In

• Take-Two Interactive (TTWO) PT Raised to $368 at BofA Securities
• Public Storage (PSA) PT Raised to $338 at Truist Securities
• Alaska Air (ALK) PT Raised to $62 at UBS on Updated Q2 Estimates